Medicare currently does not cover glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Wegovy) or tirzepatide (Zepbound), when prescribed specifically for chronic weight management. While the Social Security Act generally prohibits Medicare from covering weight-loss drugs, the program does provide coverage for these medications when they are prescribed to treat type 2 diabetes or to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity.
Why does Medicare restrict coverage for weight-loss drugs?
The federal government’s stance on weight-loss medications is rooted in the Social Security Act of 1965. Under Section 1861(d) of the Act, Congress explicitly excluded medications used for "weight loss" or "weight control" from the definition of covered Part D drugs. Because of this statutory prohibition, the Centers for Medicare & Medicaid Services (CMS) lacks the regulatory authority to add these drugs to the Medicare formulary for weight loss, even when they are clinically indicated for obesity.
According to the Kaiser Family Foundation (KFF), this legislative barrier remains the primary hurdle for millions of Medicare beneficiaries seeking access to newer, highly effective anti-obesity medications.
When are GLP-1 agonists covered by Medicare?
While Medicare does not cover weight-loss drugs, it does cover GLP-1 receptor agonists when they are used to manage other chronic conditions.
- Type 2 Diabetes: Drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. Medicare Part D plans cover these medications when prescribed for this purpose.
- Cardiovascular Risk Reduction: In March 2024, the CMS issued guidance clarifying that Wegovy is a covered Part D drug when prescribed to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight.
Because Wegovy and Ozempic are both semaglutide, the distinction in coverage often depends entirely on the FDA-approved indication for which the prescription is written.
What is the status of the "Medicare GLP-1 Bridge" program?
There is currently no official federal program titled the "Medicare GLP-1 Bridge." Legislative efforts, such as the Treat and Reduce Obesity Act, have been introduced in Congress to amend the Social Security Act and allow Medicare to cover anti-obesity medications.
As of late 2024, these bills have not been enacted into law. Any claims regarding an active "bridge" program or temporary expansion of coverage for general weight loss are inaccurate and do not reflect current CMS policy.
Key Takeaways for Medicare Beneficiaries
- Check Your Diagnosis: Coverage is contingent on the FDA-approved use of the medication. If you have type 2 diabetes or a diagnosis of cardiovascular disease with obesity, your plan may cover a GLP-1 agonist.
- Review Your Formulary: Medicare Part D plans vary in their specific drug formularies and prior authorization requirements. You should check the "Evidence of Coverage" document for your specific plan.
- Consult Your Physician: Your doctor determines the medical necessity of your prescription. They can help clarify whether your medical history qualifies you for coverage under current FDA indications.
- Monitor Legislative Updates: Because the restriction on weight-loss drugs is federal law, only an act of Congress can change the policy. Organizations like the American Medical Association (AMA) continue to advocate for expanded access to these treatments.
If you are struggling to afford a medication that your doctor has prescribed, you may qualify for the Medicare Extra Help program, which assists with Part D premiums, deductibles, and coinsurance for those with limited income and resources.